Self-Expanding Nitinol Stent vs Percutaneous Transluminal Angioplasty in the Treatment of Femoropopliteal Lesions: 3-Year Data From the SM-01 Trial.
Osamu IidaKazushi UrasawaYasuo KomuraYoshimitsu SogaNaoto InoueHidehiko HaraJunji YajimaShigeru NakamuraTakao OhkiHiroshi AndoKeisuke HiranoYuki HoritaKimihiko KichikawaYoshiaki YokoiAkira MiyamotoMasato NakamuraMitsuyoshi TakaharaToshiaki ManoShinsuke NantoPublished in: Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists (2019)
The S.M.A.R.T. stent maintained a higher primary patency rate than PTA at 3 years in this randomized trial; the need for clinically-driven revascularization was similar for both therapies.
Keyphrases
- clinical trial
- electronic health record
- study protocol
- minimally invasive
- phase iii
- coronary artery bypass grafting
- ultrasound guided
- big data
- phase ii
- randomized controlled trial
- combination therapy
- machine learning
- coronary artery disease
- acute coronary syndrome
- data analysis
- artificial intelligence
- replacement therapy
- placebo controlled